Mammal-specific growth deficient arthroviruses
By introducing dysfunctional furin cleavage sites in arbitrary viruses, ensuring that they do not replicate in mammals but grow in insect cells, the safety and productivity problems of arbitrary virus treatment methods in the prior art are solved. , provides efficient immunogenic materials.
Patent Information
- Application Number
- CN202411098066.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2017-09-11
- Filing Date
- 2018-09-11
- Publication Date
- 2024-12-06
AI Technical Summary
The prior art is difficult to develop a reliable, safe and effective arbovirus treatment method, especially in mammals where infectious virus replication is not triggered, and can grow in insect cells for large-scale production of arbovirus antigens. .
By introducing dysfunctional arboviruses, especially by enhancing the alteration of furin cleavage sites, which do not replicate in mammalian cells but grow in insect cells, arbovirus antigens are produced to stimulate the immune response, and by These altered viruses are produced at scale in insect cells.
It realizes that no infectious viral progeny particles are produced in mammals, and at the same time, the efficient production of arbovirus antigens in insect cells is provided, providing safe and effective immunogenic materials that can induce immune responses in mammals without causing disease.
Smart Images

Figure CN119082051A_ABST
Abstract
Description
[0001] This application is a divisional application of the PCT international application PCT / US2018 / 050341 filed on September 11, 2018, which entered the Chinese national phase on May 11, 2020, and the Chinese patent application number is 201880072902.2 and the invention name is "Mammalian-specific growth-defective insect-borne virus". Technical Field
[0002] The present invention relates generally to arboviruses, a small group of viruses with unique and unusual replication properties in insect cells and human cells. The present invention relates to mutated arboviruses and their use as immunogens. In certain aspects, the present invention relates to altered arboviruses that no longer replicate in mammalian host cells, but continue to replicate in insect cells and can be harvested therefrom, and still continue to express and present arbovirus antigens to the mammalian immune system.
[0003] The present invention relates to the Arboviridae family of viruses. A fundamental property of Arboviruses is replication in mammalian and insect cells. Many Arboviruses are transmitted to mammals by ticks or mosquitoes. Under one classification scheme, Arboviruses include the genera Flavivirus, Alphavirus, and Orthobunyavirus. Under another classification scheme, Arboviruses include the families Bunyaviridae, Flaviviridae, Reoviridae, and Togaviridae. Examples of arboviruses include African Swine Fever virus, Tick-borne Encephalitis virus, Rift Valley Fever virus, Colorado Tick Fever virus, Equine Encephalosis virus, Chikungunya virus, Dengue virus (DV), Zika virus (ZV), and West Nile virus.
[0004] Flaviviruses have been studied, in part, due to human pathology, see, for example, Gubler & Kuno, eds.: Dengue and Dengue Hemorrhagic Fever. Wallingford, CAB International, 1997; and Porterfield; Exotic Viral Infections. Chapman and Hall Medical, London, 1995.
[0005] The flavivirus genome consists of a single linear, single-stranded, positive-sense RNA. The positive-strand RNA infects suitable host cells. The total genome may be 10 to 11 kb. There is no 3' polyadenylation. There is a methylated cap at the 5' end.
[0006] The flavivirus genome does not contain an internal ribosome entry site (IRES) that provides a translation initiation site for the host ribosome. Instead, flaviviruses use ribosome scanning to initiate protein synthesis.
[0007] Flavivirus virions can be spherical with a diameter of 40-65 nm. Under the lipid envelope is an icosahedral capsid with a diameter of about 25-30 nm.
[0008] DV (types 1-5), Yellow Fever virus, Japanese Encephalitis virus, Tick-borne encephalitis virus, and West Nile virus are pathogens that cause significant morbidity and mortality in humans.
[0009] For example, the yellow fever virus is capable of causing epidemics. In the first cycle, the virus is transmitted by Aedes africanus and other Aedes mosquitoes (in Africa) or by Hemogogus mosquitoes (in the Americas); monkeys serve as reservoirs, and humans who are infected are generally those who go deep into forests and jungles and are exposed to these vectors. In the second cycle, the house mosquito, Aedes aegypti, which lives in close association with humans, may transmit the virus directly to humans, the only host in this cycle.
[0010] Flaviviruses cause other diseases such as Murray Valley Encephalitis, Rocio Encephalitis, and Powassan Encephalitis, as well as West Nile fever and Zika fever, which have recently been observed in the Americas.
[0011] Several flaviviruses, including Louping Ill virus, which causes a neurological disease in sheep, West Nile virus, which causes equine encephalitis, and Japanese encephalitis virus, which also causes equine encephalitis as well as stillbirths in pigs, are veterinary pathogens of commercial importance.
[0012] Given the urgent need for arbovirus treatments, a reliable method for preparing safe and effective arbovirus therapeutic compositions is needed. In theory, live attenuated vaccines produce the most effective, long-lasting, and specific immunity, while inactivated virus vaccines, including recombinant subunit vaccines, provide a higher level of safety. The ideal vaccine would be one that produces the efficacy of live vaccines and the safety of subunit vaccines.
[0013] Those objectives were achieved in developing a scalable method for preparing mammal-specific growth-restricted arboviruses. The growth-defective target virus is present in infected mammals and expresses arboviral antigens and elicits an immune response to the arboviral antigens, but does not produce progeny virus in mammalian cells, so the infected cells do not contribute to the spread of cellular infection and pathology in the mammalian host. The proliferation of the growth-restricted target virus in insect cells is not disturbed. Therefore, the dysfunctional target virus can be economically produced in insect cell lines. Summary of the invention
[0014] The present invention relates to materials and methods for preparing growth-restricted arboviral particles that continue to replicate in insect cells but no longer replicate (or replicate at a low level) in mammalian cells (such as human cells), so that the infected mammalian cells do not produce progeny viruses. The target arbovirus infects host mammalian cells, can replicate in the host mammalian cells, and produces arboviral proteins that are recognized by the mammalian host immune system (e.g., through cellular and / or humoral responses), but does not produce and release progeny arboviral particles. The defective target virus contains all the necessary genes to ensure viral genome replication and production of arboviral proteins, which can be released from infected cells or can be expressed on the surface of host cells, but do not produce progeny viruses from infected host mammalian cells. Therefore, the target arboviral particles can be as immunogenic as wild-type viruses, but these particles should not contribute much (if any) to the disease or condition in the infected host because the modified target arbovirus has reduced (if any) replication in mammalian cells.
[0015] The growth restricted arbovirus of interest does not readily propagate in mammalian or human cells and produces and releases 4 logs or less, 5 logs or less, 6 logs or less, 7 logs or less, 8 logs or less, 9 logs or less, or no progeny arbovirus, as compared to the level or amount of progeny virus produced in cells of the same type infected with the same wild-type arbovirus or in the sample before being treated to become growth restricted.
[0016] On the other hand, the growth-restricted or growth-deficient arbovirus of interest readily proliferates in insect cells (e.g., arthropod cells) to produce similar progeny arboviruses. The level of progeny arbovirus produced by the insect cells can be about equal to or can exceed the level or amount of progeny virus produced by a suitable control wild-type arbovirus of the same species, or the level or amount of progeny virus produced by a suitable control wild-type arbovirus of a sample that is treated to become growth-restricted in the same insect cells.
[0017] In embodiments, the defective arbovirus of interest comprises an enhanced furin activity (i.e., it can be cleaved at a higher rate, can be cleaved more efficiently, or both, compared to a wild-type arbovirus of the same species or to a wild-type arbovirus of a sample before being treated to become growth restricted). Furin cleavage of the precursor polyprotein is essential for maturation of arbovirus progeny particles. In some arboviruses, furin cleavage occurs at the juncture of pr and M. Thus, the defective arbovirus of interest comprises an enhanced furin activity at, in, or around the prM protein or polypeptide. In some arboviruses, furin cleavage occurs at the juncture of E3 and E2. Thus, the defective arbovirus of interest comprises an enhanced furin activity at, in, or around the precursor E2 protein or polypeptide.
[0018] The growth-restricted arbovirus of interest comprises an alteration in the furin consensus tetrapeptide, which may be, for example, at the junction of pr and M; an alteration upstream of the consensus tetrapeptide (e.g., in the amino-terminal direction in the pr polypeptide); an alteration downstream of the consensus tetrapeptide (e.g., in the carboxyl-terminal direction in the M protein); or a combination thereof.
[0019] In embodiments, the arbovirus is dengue virus (DV), which comprises a prM polyprotein.
[0020] In embodiments, one or more amino acid substitutions in and / or around the furin cleavage site between pr and M result in a virus with enhanced furin cleavage of prM; propagates in insect cells; and does not propagate in mammalian or human cells.
[0021] In an embodiment, the enhanced furin activity in DV is obtained by one or more of the following ways: 1) changes in the 8 amino acid stretch upstream (amino terminal direction) of the furin recognition and cleavage site starting from the 80th amino acid of the prM polypeptide of DV, i.e., amino acids 80-87 of prM; 2) changes in the tetrapeptide furin recognition site; 3) changes in the 39 amino acid stretch downstream (carboxyl terminal direction) of the furin recognition and cleavage site, i.e., amino acids 92-130 of prM; 4) changes upstream of amino acid 80; 5) changes downstream of amino acid 130. Any combination of the above may be present, for example, 1), 2) and 3 may be present. Changes 1), 2) and 3) may be present.
[0022] In an embodiment, the DV furin cleavage site in the prM protein, NH2-(88)Arg-Glu-Lys-Arg-COOH / (SEQ ID NO:1), wherein cleavage occurs after the Lys-Arg residue (and indicated by the " / " in the cleavage recognition site indicated above), is altered at the Glu site to enhance furin cleavage.
[0023] In an embodiment, Glu can be replaced by any amino acid.
[0024] In an embodiment, the amino acid replacing Glu is a non-acidic, non-neutral amino acid, such as Gln, Asn, Gly, Lys, Arg, His, Thr, Ser, Tyr, Met or Cys. In an embodiment, the replacement amino acid does not contain sulfur. In an embodiment, the replacement amino acid does not contain a hydroxyl group in the R group side chain. In an embodiment, the replacement amino acid is a basic amino acid. In an embodiment, the replacement amino acid is Lys, Arg or His. In an embodiment, the replacement amino acid is Arg.
[0025] In an embodiment, the defective DV of interest comprises one or more changes in the polypeptide sequence upstream of SEQ ID NO: 1, for example, in the 8 amino acids upstream of the Arg-Glu residue. In an embodiment, the defective DV of interest comprises one or more changes in the polypeptide sequence downstream of SEQ ID NO: 1, for example, in the 39 amino acids downstream of the Lys-Arg residue. The changes may be at or in the furin recognition or cleavage site. The changes may be in the M protein. The changes may be located in the first 39 amino terminal amino acids of the membrane protein. The changes may be in the pr polypeptide. The changes may be located in the last 8 carboxyl terminal amino acids of the pr polypeptide.
[0026] This change or combination of changes reduces or inactivates the replication, maturation, and release of DV from infected mammalian cells. Thus, infected mammalian cells contain DV antigens and present them to the mammalian host immune system, but infected mammalian cells do not release infectious progeny DV particles.
[0027] However, these changes at or around the furin cleavage site do not invalidate the replication of the target DV in insect cells, thereby providing a method and means for producing DV particles, the particles comprising the altered furin sites disclosed herein, for infecting mammalian cells but not replicating in mammalian cells. Propagation in insect cells is robust, providing high virus yields, and the growth or production of DV in insect cells is scalable to produce virus particles in larger volumes, quantities, and reactions.
[0028] In embodiments, the arbovirus is Zika virus (ZV), which comprises a prM polyprotein.
[0029] The furin cleavage site of ZV is located after the 93rd amino acid of prM. In embodiments, at the serine residue of the tetrapeptide furin recognition site, the prM sequence located upstream of the ZV furin recognition site His-His-Lys-Lys-Gly-Glu-Ala-Arg-Arg-Ser-Arg-Arg / (SEQ ID NO:2) and including the ZV furin recognition site is modified (cutting occurs after the 4th Arg in the above sequence), to provide a sequence of 5 arginine residues to enhance furin cleavage. In embodiments, the glutamic acid residue in this region can be changed to histidine to enhance furin cleavage. Other changes can be made to the sequence of the above residues. Changes can be made upstream of the 82nd amino acid and / or downstream of the 93rd amino acid.
[0030] Enhanced furin activity in ZV can be obtained by one or more of the following methods: (1) changes in one or more amino acids upstream of the ZV furin cleavage site, for example, in the 8 residue sequence starting from the 82nd amino acid residue at the N-terminus of prM (i.e., amino acid residues 82-89 of prM), but can be upstream of amino acid 82; (2) changes in the ZV furin tetrapeptide cleavage site; and (3) changes in one or more amino acid residues downstream of the furin cleavage site (i.e., amino acid 94 and below), for example, an amino acid stretch of 26 residues downstream of the tetrapeptide. Any combination of (1), (2) and (3) can be present.
[0031] Growth of the ZV of interest in mammalian cells is minimized or substantially absent, whereas growth of the disabled ZV in insect cells is substantially unaffected.
[0032] Other features and advantages of the present invention are described in and will be apparent from the following detailed description and accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] Figure 1 Depicted are survival curves comprising data obtained from mice receiving phosphate buffered saline (PBS) as a control or the DV mutant of interest (D2-89R) prior to challenge with wild-type DV.
[0034] Figure 2 Depicted are survival curves comprising data obtained from mice receiving phosphate-buffered saline (PBS) as a control or the SV mutant of interest (M2) prior to challenge with wild-type SV.
[0035] Figure 3 Depicted are safety profiles containing data obtained from mice receiving wild-type SV or the SV M2 mutant. DETAILED DESCRIPTION
[0036] As used herein, "dysfunctionality" or its grammatical form, means the enhancement of the characteristic or function caused by the change or change compared to the functional level or characteristic observed before or without the change or change. For example, the enzyme site of the change and dysfunction may be such an enzyme site: that is, it is always recognized by the enzyme or is cut by a homologous enzyme at a higher rate, a more effective manner, etc., and the result is an increase in the level or quantity of the enzyme reaction product. For example, in embodiments, the furin cleavage site of the dysfunction is cut at a rate or value observed at an enhanced or higher rate than the furin cleavage site of the non-dysfunctional disorder. Therefore, the result is a decrease in the number or level of prM in the infected cell. A synonym for dysfunction is "defective" or its grammatical form.
[0037] "Enhanced" or its grammatical form, is a measure or level higher than a base or reference level or measure. The basal level can be determined by sampling some units and taking an average value, or by obtaining a derived population mean value from the literature. In embodiments, the enhanced level is any level higher than the level present in the control sample. Therefore, in biological assays, chemical assays, etc., for example, two samples can be run side by side, a suspected experimental sample with an enhanced measure and a control, which can be a sample from a population representative of a known wild type, normal, unchanged, non-mutated, etc., showing a higher measure in the experimental sample, for example, a larger number of products, faster kinetics, larger products, etc. In embodiments, the basal level is the level present in the wild-type unit. In embodiments, the enhanced enzyme activity level including the increase. In embodiments, the enhanced catalytic activity level including the increase. In embodiments, the enhanced solubility activity level including the increase. In embodiments, the enhanced polypeptide cleavage level of furin including the increase. In embodiments, by comparing the prM quantity in the sample from the cell infected by the target mutant and the cell infected by the wild-type virus, the enhanced furin activity can be revealed. In embodiments, enhanced furin activity may be revealed by decreased levels of prM or increased levels of pr or M in a comparison of the mutant and wild type.
[0038] "Alteration" or its grammatical form, is a change or modification of the wild-type amino acid sequence at one or more residues. Thus, the altered polypeptide may comprise an allele. The change may be an amino acid substitution, deletion or insertion, which may comprise two or more amino acids at one site of the wild-type sequence. The alteration produces a functionally impaired virus of interest.
[0039] "Stretch" or its grammatical form refers to consecutive nucleotides of a nucleic acid, or consecutive amino acids of a protein. The consecutive nucleotides of a nucleic acid (a stretch of nucleotides) are polymerized into a linear oligonucleotide. The consecutive amino acids of a protein (a stretch of amino acids) are polymerized into a linear oligopeptide.
[0040] "Propagation" or its grammatical form includes the following processes: virus infects compatible host cells; replicates in the infected cells to produce progeny viruses; and the infected cells release the progeny viruses into the extracellular space. Synonyms include "reproduction", "replication", "growth" and the like.
[0041] "Immunogenicity" or its grammatical form, includes producing or causing an immune response in a host. Therefore, in an embodiment, immunogenicity includes having an epitope or determinant. In an embodiment, for example, an immunogenic composition is a composition carrying an epitope or determinant, which, when introduced into a host, triggers an immune response of the host's immune system to the epitope or determinant. The immune response can "remove" the immunogenic composition from the host to some extent, where "removal" can include actual destruction of the composition, i.e., denaturation or digestion of the composition; isolation of the composition, so that the composition is contained in a structure that makes the composition inert; detoxification of the composition; neutralization of the composition; making the composition biologically inert; making the composition safe for the host and safe in the host, etc. Immunogenicity does not mean or guarantee that immune protection is produced in any exposed host. The immune response can be humoral, cellular, etc., or a combination thereof.
[0042] "Does not replicate in human or mammalian cells," "does not proliferate in human or mammalian cells," "does not grow in human or mammalian cells," "does not reproduce in human or mammalian cells," "growth restricted in human or mammalian cells," "growth restricted," "growth defective," equivalents of these phrases, grammatical forms of these phrases, and the like are synonymous or synonymous terms or phrases (as described herein) and include human or mammalian cells infected with the mutant virus of interest that produces 4 logs or less, 5 logs or less, 6 logs or less, 7 logs or less, 8 logs or less, 9 logs or less, or no progeny arbovirus as compared to the level or amount of progeny virus produced by the same type of cells infected with a wild-type arbovirus of the same species, strain, line, etc.; by similar cells infected with a non-dysfunctional virus (as described herein); or by an appropriate and acceptable negative control.
[0043] "Replicate in insect cells," "proliferate in insect cells," "grow in insect cells," "regenerate in insect cells," "not growth restricted in insect cells," "not growth defective," "not growth restricted," equivalents of these phrases, grammatical forms of these phrases, and the like are synonymous or synonymous terms or phrases (as described herein) and include insect cells infected with the mutant virus of interest producing comparable or greater levels or quantities of progeny virus as compared to the level or amount of progeny virus produced by the same type of insect cells infected with the same species, strain, or the like wild-type arbovirus; by similar cells infected with a non-dysfunctional virus (as described herein); or by an appropriate and acceptable negative control.
[0044] "About" is an approximation relative to a value such that there is a certain amount of variability, which is reflected, for example, in error or deviation, providing a range around the value, wherein the limits of the range are 10% less than the value (including the value) and 10% greater than the value. Thus, as used herein, by referring to about 50, it is understood that the value can range from 45 to 55. Synonymous terms include "substantially" and "essentially".
[0045] "Scalable" or its grammatical forms, is a method performed on a bench or laboratory scale that can be transferred to a larger scale or performance, for example, a method for commercial production of food, beverages, consumer products, industrial chemicals, etc., where the volume of the reaction vessel can reach hundreds or thousands of liters. Thus, in the context of the present invention, insect cell culture can be performed at tens, hundreds or thousands of liters of volume, number, reaction, etc. or larger volumes, numbers, reactions.
[0046] "Wild type" or its grammatical form, relates to naturally occurring arbovirus, which is usually the most common or most prevalent form, trait, gene, protein, phenotype, etc. in a population. In embodiments, synonyms are "typical (type)" or "reference (reference)" arbovirus. Population traits can be determined by multiple alleles of a single locus or by polygenes. Therefore, when alleles or polygenes produce the same trait or substantially the same trait, the alleles or polygene sets are considered to be equivalent herein. Wild-type arbovirus does not contain a dysfunctional furin protease site that causes enhanced furin protease cleavage, such as present in the altered arbovirus of interest. In embodiments, comparisons are made herein to show the properties of the modified arbovirus of interest compared to a normal or wild-type arbovirus of interest that does not contain a dysfunctional furin protease cleavage site. In embodiments, the arbovirus of interest has normal properties or properties that are roughly the same as those in the reference arbovirus, such as growth in insect cells. For example, in embodiments, the reference DV is a serotype 2, New Guinea strain available from ATCC (Accession No. VR-1584). Thus, references herein to DV prM and its amino acid numbering may be to prM relative to VR-1584; or to prM and its amino acid numbering relative to the wild-type form of a mutant DV. In embodiments, a reference ZV may be available from ATCC as Accession No. VR-1838. Thus, references herein to ZV prM and its amino acid numbering may be to prM relative to VR-1838; or to the wild-type form of a mutant ZV. The arbovirus of interest, like the wild-type arbovirus, propagates in insect cells. However, for the amino acid numbering herein, the numbering in one strain, lineage, species, etc. may not directly correspond to the numbering in another strain, lineage, species, etc. due to inherent population variation, polymorphism, or variability in a population. Thus, the numbering of the position of any one polypeptide, cleavage site, etc. herein is not absolute, as the numbering may vary even in one line, strain, species, etc. due to naturally occurring variation. Therefore, the numbering used in this article is relative to specific cells, viruses, etc., and should not be interpreted as absolutely representing all arboviruses, and the numbering in all arboviruses is the same as the numbering presented in this article. On the contrary, various features all provide landmarks (landmarks) for identifying sites, and enable technicians to implement the claimed subject matter with any arbovirus as a design choice. For example, the furin proteinase at the junction of pr and M has a tetrapeptide, the downstream or carboxyl terminal of pr, the upstream or amino terminal of M is a landmark that can be used for directional manipulation and changing proteins.Thus, in one embodiment, numbering takes into account the number of amino acids in the tetrapeptide to determine if there is variability in the size of pr and M, and if so, among different arboviruses, adjusting or correlating between what is taught herein and what is used by the skilled artisan to provide an appropriate frame of reference.
[0047] In serotypes 1-4 of DV, the "prM" protein or polypeptide of DV is 166 amino acids in length and is cleaved by furin after amino acid position 91 to produce the pr polypeptide and M protein. The wild-type prM amino acid sequence of the NGC strain of DV2 is: FHLTTRNGEP HMIVSRQEKG KSLLFKTEDG VNMCTLMAMD LGELCEDTIT YNCPLLRQNEPEDIDCWCNS TSTWVTYGTC TTTGEHRREK RSVALVPHVG MGLETRTETW MSSEGAWKHA QRIETWILRHPGFTIMAAIL AYTIGTTYFQ RVLIFILLTA VAPSMT (SEQ ID NO: 8). As is well known, natural variation can find that the wild-type strain has one or more amino acid changes in the sequence provided in SEQ ID NO: 8 without destroying or enhancing the cleavage of prM by furin or reducing proliferation in mammalian cells. The target SEQ ID NO: 8 for the alteration is a sequence that exhibits enhanced furin cleavage; the virus proliferates in insect cells, but the virus proliferates little or not in mammalian cells.
[0048] The "prM" protein or polypeptide of ZV is 168 amino acids in length and is cleaved by furin after amino acid position 93 to produce the pr polypeptide and the M protein. The wild-type prM amino acid sequence is AEITRRGSAY YMYLDRSDAGKAISFATTLG VNKCHVQIMD LGHMCDATMS YECPMLDEGV EPDDVDCWCN TTSTWVVYGT CHHKKGEARRSRRAVTLPSH STRKLQTRSQ TWLESREYTK HLIKVENWIF RNPGFALVAV AIAWLLGSST SQKVIYLVMILLIAPAYS (SEQ ID NO:9). As is well known, natural variation can find one or more amino acid changes in the wild-type strain in the sequence provided by SEQ ID NO:9 without destroying or enhancing the cleavage of prM by furin or reducing proliferation in mammalian cells. The altered SEQ ID NO:9 is a sequence that exhibits enhanced furin cleavage; the virus proliferates in insect cells, but the virus does not proliferate in mammalian cells.
[0049] As used herein, "furin cleavage site", "furin recognition site" and "furin recognition and cleavage site" are interchangeable and equivalent. It is well known that furin generally recognizes the consensus tetrapeptide Arg-X-Lys / Arg-Arg (SEQ ID NO: 16), where X is any amino acid (sequences upstream and / or downstream of the tetrapeptide may also include a furin cleavage site), and cleaves the peptide bond downstream of the tetrapeptide or the peptide bond on the carboxyl terminus. Generally speaking, in arboviruses, the furin cleavage site is present at the junction of two polypeptides in the precursor polyprotein, such as prM and precursor E2 (prE2). In some arboviruses, the furin cleavage site is present at the junction of pr and M. In other arboviruses with different genomic organizations and without prM, for example, some alphaviruses, the furin cleavage site is present at the junction of E3 and E2.
[0050] As used herein, "X logs or lower", "X logs or less", or "X logs or fewer" (where X is a rational number) refers to a logarithmic scale used to describe the number of viral particles. As is known, this scale is nonlinear and is based on an order of magnitude with a base of 10. The log scale is used when the range of values for a parameter is large. Thus, 4logs reflects a difference of 10 between two values. 4, that is, if one value is 10,000 units less or greater than another value, 5logs reflects the difference between the two values as 10 5 , i.e., one value is 100,000 units less or greater than another value, etc. Phrases containing the words "lower," "less," or "fewer" refer to quantities that are numerically lower, numerically smaller, etc., or, in the context of this document, to fewer viral particles. Thus, "4 logs or less" means that the difference between two values is 10 4 , 10 4.5 , 10 5 etc., which means that the number of virus particles produced in one sample is 10,000 less, approximately 31,600 less, or approximately 100,000 less than another sample, and in the context of this article means that one sample contains 10,000 fewer virus particles than another sample.
[0051] The present invention focuses on the manipulation of the arbovirus genome to produce mammalian cell-specific, growth-defective arboviruses, wherein mammalian cells infected with such arboviruses do not release mature progeny viruses, but instead continue to express arbovirus epitopes and determinants that can be recognized by the mammalian host, such as the determinants expressed by the M and E proteins. A cellular and / or humoral response to the arbovirus can be generated in the mammalian host. The arbovirus of interest is substantially similar to the wild-type virus, thus providing the mammalian host immune system with universal arbovirus epitopes that can be found in arboviruses, wild-type arboviruses. The arbovirus of interest is not able to replicate at all in the host mammalian cell, and therefore cannot cause infection of other host mammalian cells and cannot cause pathology or disease in the host.
[0052] Thus, the present invention relates to defective or dysfunctional arboviruses that include and express most, if not all, structural proteins, or at least most polypeptides that contain determinants or epitopes for antibodies or immune cells produced by the infected host against the arbovirus. Thus, for example, for Flavivirus, it is preferred that most of the pr, M and / or E proteins are expressed thereby, as these proteins contain immunogenic sites of the wild-type virus. The C protein will not be substantially targeted by the host immune system, but may be present.
[0053] All known arboviruses require furin cleavage of the precursor polyprotein for proper viral maturation and release from host cells, such as the cleavage of prE2 into E3 and E2 in some alphavirus genera and the cleavage of prM into pr and M in some flavivirus genera, for proper viral maturation and eventual release of progeny viruses from infected cells.
[0054] The mutant arbovirus of interest comprises an altered or dysfunctional furin cleavage site, such as at prE2 or prM, and optionally comprises changes upstream and / or downstream from the common furin cleavage site, resulting in enhanced cleavage of, for example, prE2 or prM by furin, resulting in a virus that continues to replicate in insect cells, but no longer replicates or replicates very poorly in mammalian (including, of course, human) cells. Thus, changes at or around the furin cleavage site, such as prE2 or prM, in an arbovirus produce a growth-restricted virus that continues to grow in insect cells, but no longer grows or grows very poorly in human or mammalian cells, wherein growth indicates that the infected cells have released progeny virus.
[0055] In general, during the maturation of early flavivirus particles in the Golgi apparatus, immature particles present a trimer of prM and E proteins, which are rearranged during passage through the Golgi apparatus (possibly due to changes in pH) to form a smooth surface on the particle. The rearrangement or transformation of the spike exposes the furin cleavage site of prM. prM is cleaved by furin, and some pr fragments (perhaps based on the pH in the Golgi apparatus) remain attached to the particle. It is believed that the pr fragments can prevent membrane fusion. When the initial particles are released from the Golgi apparatus into the extracellular environment, pr is released from the initial particles to form mature particles, which can fuse with the cell membrane to be released from the cell. Some developing particles may not mature. However, viral proteins are attached to the intracellular membrane and are incorporated into the cell membrane, where the viral proteins are expressed on the cell surface. Viral particles and components can be released into the environment when cells die and lyse.
[0056] Although not wanting to be bound by theory, the mutant viral genome of the target containing an altered furin cleavage site in prM (which can enhance the cleavage of prM) may induce prM to be cleaved before the developing virion enters the Golgi apparatus, which may be under different pH conditions, resulting in pr not being connected to the particle surface because the particle enters and resides in the Golgi apparatus. Therefore, there is no pr to prevent membrane fusion, properly prevent the maturation of the virion when it passes through the Golgi apparatus, and capture it in the Golgi apparatus. Since prM is cut prematurely before entering the Golgi apparatus, the target arboviral particle does not contain pr, and therefore cannot be properly processed in the Golgi apparatus, resulting in the virion binding and fusion to the Golgi membrane, but will not be released from the Golgi membrane, and therefore cannot be released from the cell.
[0057] However, this process is not altered in insect cells, where, for example, the timing and / or efficiency of furin cleavage of prE2 or prM is not associated with or prevents proper maturation and release of arboviral particles from host insect cells. Thus, infected insect cells produce progeny arbovirus at levels comparable to, the same as, or greater than those found in insect cells infected with wild-type virus.
[0058] The furin consensus tetrapeptide (RXK / RR (SEQ ID NO: 16)) of the target arbovirus is located, for example, at the junction of E3 and E2, and at the junction of the pr polypeptide and the M protein. The amino acids of the tetrapeptide are altered by amino acid substitution, directed mutagenesis of a nucleic acid encoding the amino acids, etc., by known methods, such as constructing the tetrapeptide to contain, for example, Arg as a second or X site. The altered furin site is placed, for example, in the full-length nucleic acid by homologous recombination, for example, by known methods. The cDNA can be subjected to nucleic acid manipulation and then transcribed to form a viral RNA comprising an altered furin cleavage coding sequence as taught herein and by methods known in the art. The viral nucleic acid can be packaged into particles, for example, by electroporating the viral RNA into a suitable host cell. The transfected cells are cultured, the production of viral particles is monitored, and viral particles carrying RNA comprising an altered furin cleavage site coding region are obtained. DNA, RNA, vectors, host cells, etc. are known and some reagents are commercially available, see, for example, Polo et al., Zeng et al., Khromykh et al. J Virol 75 (10) 4633-4640, 2001; Gehrke et al., J Virol 77 (6) 8924-8933, 2003; and Shustov et al., J Virol 81 (21) 11737-11748, 2007. The virions are then used to infect appropriate cells and cultured as known in the art. The production of progeny virus is monitored using the methods taught herein to determine whether the changes affect viral replication in mammalian cells but not in insect cells, and the extent of the changes in proliferation in these two types of cells.
[0059] The present invention relates in part to Flaviviruses, some of which include the prM polyprotein.
[0060] In embodiments, the invention relates to DV (eg, any of serotypes 1-5).
[0061] The DV genome consists of a single linear, single-stranded, positive-sense RNA. The total genome can be 10 to 11 kb. There is no 3' polyadenylation. There is a methylated cap at the 5' end. The DV genome does not contain an internal ribosome entry site (IRES) that provides a translation start site for the host ribosome. Instead, DV uses ribosome scanning to start protein synthesis.
[0062] Dengue virions are spherical with a diameter of 40-65 nm. Under the lipid envelope is an icosahedral capsid with a diameter of about 25-30 nm.
[0063] Dengue fever is an acute infectious disease characterized by biphasic fever, headache, pain in various parts of the body, prostration, rash, lymphadenopathy and leukopenia (Holstead, 1980, Immunological parameters of togavirus disease syndromes, p. 107-173, in Schlesinger (ed.), "The Togaviruses," Academic Press, Inc., NY; and Sabin, 1959, Dengue, p. 361-373, in Rivers & Horsfall (eds.), "Viral and Rickettsial Infections of Man," JB Lippincott Co., Philadelphia). DV is transmitted by mosquitoes. Infection with one dengue serotype provides lifelong immunity to that subtype, but there is no cross-protective immunity to other serotypes.
[0064] Dengue hemorrhagic fever (DHF) is a severe febrile illness characterized by abnormal hemostasis and increased vascular permeability, which in some cases leads to hypovolemic shock syndrome, dengue shock syndrome (DSS) (WHO: 1975. Technical Guides for Diagnosis, Treatment, Surveillance, Prevention and Control of Dengue Hemorrhagic Fever, Geneva, CH). The mechanism of DHF / DSS may be different in different cases. The main factors leading to DHF / DSS may include viral virulence, patient health status and secondary infection with different serotypes of DV.
[0065] There are currently five DV serotypes, DV1, 2, 3, 4 and 5. Immunity to one serotype does not generally confer immunity to another serotype.
[0066] Confusingly, humans do not always respond in the same way to various serotypes. Thus, a person who is simultaneously infected with at least two DV serotypes may only develop an immune response to one serotype. In addition, subsequent infection, often with a serotype different from the primary or prior infection (but when the first or prior infection was benign, mild, or asymptomatic), can result in more severe disease and pathology.
[0067] The reasons for serotype dominance, selectivity, or interference are unclear. They may be due to in situ viral replication, growth, maturation, and release from host cells, or antigen presentation may direct the host immune response to a specific serotype.
[0068] Regardless, less predictable host responses, serotype interference, and asymptomatic infection present many obstacles to the development of effective multivalent vaccines.
[0069] Current multivalent live vaccines do not immunize equally against all serotypes, even when the relative amounts of each serotype in the vaccine are varied in an attempt to compensate for skewed immune responses.
[0070] In the implementation of the subject matter of interest, various DV genomes were constructed with different amino acid substitutions at the following positions: at the Glu residue of the prM furin cleavage site; upstream of the common tetrapeptide, for example, in the upstream segment of 8 amino acids adjacent to the common sequence (i.e., amino acids 88-91); downstream of the common tetrapeptide, for example, in the downstream segment of 39 amino acids adjacent to the common sequence of amino acids 88-91, i.e., in amino acids 92-130 (i.e., in amino acids 80-130 (inclusive) of prM). The change in amino acids enhances furin cleavage of prM. When introduced into mammalian host cells, replication and expression occur along with the production of virions. However, no mature particles to be removed from the host cells are obtained. Therefore, once the target particles infect mammalian cells, the mutant viral genome is replicated and expressed in the mammalian host cells, but the mature progeny virions are not released by the infected host mammal or human cells.
[0071] In an embodiment, the DV furin tetrapeptide cleavage site NH2-(88)Arg-Glu-Lys-Arg-COOH (SEQ ID NO: 1) in the prM protein (wherein cleavage occurs downstream of the Lys-Arg residue) is altered at the Glu position to enhance furin cleavage.
[0072] In an embodiment, Glu can be replaced by any amino acid. The replacement amino acid can be a non-acidic, non-neutral amino acid, such as Gln, Asn, Gly, Lys, Arg, His, Thr, Ser, Tyr, Met or Cys. In an embodiment, the replacement amino acid does not contain sulfur. Therefore, the replacement amino acid is a non-acidic, non-neutral amino acid other than Met or Cys. In an embodiment, the replacement amino acid does not contain an R hydroxyl. Therefore, in an embodiment, the replacement amino acid is not Tyr, Ser or Thr. In an embodiment, the replacement mutant amino acid is a basic amino acid. In an embodiment, the replacement amino acid is Lys, Arg or His. In an embodiment, the replacement amino acid is Arg.
[0073] In an embodiment, the amino acid upstream of the tetrapeptide consensus sequence is changed. For example, one amino acid (or amino terminal side) in the 8 amino acid stretch immediately upstream of the consensus sequence of the furin cleavage site is changed to enhance furin cleavage of prM ("altered upstream site"). Thus, the change may occur at amino acids 80-87 of the prM polypeptide.
[0074] In an embodiment, the amino acid downstream of the tetrapeptide consensus sequence is changed. For example, one amino acid (or carboxyl terminal side) in the 39 amino acid segment immediately downstream of the consensus sequence of the furin cleavage site is changed to enhance furin cleavage of prM ("altered downstream site"). This change can occur at amino acids 92-130 of the M polypeptide.
[0075] The DV of interest includes at least one of the following: (1) an altered furin tetrapeptide cleavage site; (2) an altered upstream site; and (3) an altered downstream site. The DV of interest may include a combination of any two of (1), (2) and (3). The DV of interest may include all three alterations.
[0076] In embodiments, the arbovirus is a ZV comprising a prM polyprotein.
[0077] The ZV genome consists of a single, single-stranded, positive-sense RNA of 10,794 bases (although some isolates vary in size [e.g., Baronti et al., Genome Announc 2(3)1-2, 2014]). In addition to the structural and nonstructural genes, there are 3' and 5' noncoding ends.
[0078] There is a lower level of polymorphism in ZV. For example, at least two subtypes are recognized, an African virus lineage and an Asian / South American virus lineage. These two lineages can be distinguished serologically, i.e., there may be variation in the envelope protein.
[0079] Symptoms of Zika fever may include fever, red eyes, joint pain, headache and a maculopapular rash, which generally lasts less than seven days. While the initial infection is not thought to be fatal to normal adults, infection during pregnancy can cause malformations and abnormalities in the developing embryo and / or fetus, such as microcephaly. Infection in adults has been associated with Guillain-Barré syndrome.
[0080] ZV is primarily transmitted by mosquitoes. After the Zika outbreak in Brazil in 2015, ZV has spread to Latin America and the Caribbean and now to the United States.
[0081] The ZV life cycle begins with the attachment of the virion to the surface of the host cell and subsequent entry into the cell via receptor-mediated endocytosis. As currently understood, acidification of the endosomal vesicle triggers conformational changes in the virion, fusion of the viral and cellular membranes, and particle disassembly. Once the genome is released into the cytoplasm, the positive-sense RNA is translated into a single polyprotein, which is processed by viral and host proteases into 10 gene products: 3 structural proteins: core protein (C), pre-membrane protein (prM), and envelope protein (E), and 7 non-structural (NS) proteins: NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5.
[0082] The furin cleavage site of ZV is located after the 93rd amino acid of prM. In embodiments, the prM protein sequence is located upstream of the furin tetrapeptide cleavage site and includes the furin tetrapeptide cleavage site His-His-Lys-Lys-Gly-Glu-Ala-Arg-Arg-Ser-Arg-Arg / (SEQ ID NO:2), wherein the cleavage occurs after the terminal Arg and is represented by a slash, wherein the serine residue is replaced by (the tetrapeptide site Arg-Ser-Arg-Arg (SEQ ID NO:10)) Arg, to provide a sequence of 5 arginine residues to enhance furin cleavage. In addition, the glutamic acid residues in the upstream segment can be changed to, for example, histidine, to enhance furin cleavage. Other changes of residues in the upstream segment enhance furin cleavage. Changes in the downstream of the tetrapeptide enhance furin cleavage. For example, changes can occur in any or all 26 amino acid segments in the downstream of the tetrapeptide to enhance furin cleavage.
[0083] Enhanced furin activity is obtained by one or more of the following: (1) changes in one or more amino acids upstream of the furin cleavage site, such as an 8-residue sequence starting from the 82nd amino acid residue of the N-terminal prM polypeptide of ZV (i.e., the 82nd-89th amino acid residues of prM); (2) changes in the furin cleavage site; and (3) changes in one or more amino acid residues downstream of the furin cleavage site (from the 94th amino acid and below), such as a 26-residue sequence downstream of the furin cleavage site. Any combination of (1), (2) and (3) may be present.
[0084] For yellow fever virus, California encephalitis virus, Rift Valley fever virus, tick-borne encephalitis virus, West Nile virus, equine encephalopathy virus, Colorado tick fever virus, chikungunya virus, African swine fever virus and other arboviruses, the furin consensus tetrapeptide recognition site is located based on the known consensus furin recognition sequence and amino acid substitutions are made to identify mutants that no longer proliferate or proliferate poorly in mammalian cells. Amino acid changes, such as substitutions, insertions, deletions, chemical modifications, etc., can also be made upstream and / or downstream of the furin consensus cleavage site.
[0085] The preparation, growth and maintenance of viruses in cell lines and animals is known. It is known to prepare mutants of arboviruses by altering the coding sequence using molecular techniques. Various tests to determine the growth of virus in cells, the production of progeny virus from cells, and other assays used in the practice of the present invention are known, and the selection thereof is a design choice.
[0086] Another object of the present invention is to develop a scalable system for producing immunogenic arboviruses having a composition of interest. This object is achieved by producing an arbovirus of interest that expresses a dysfunctional furin cleavage site that is cleaved by furin at an enhanced level in an insect cell line (e.g., an arthropod cell line, such as a tick or mosquito cell line), wherein materials and methods for large-scale viral production by insect cells are known and available. Arthropod cell lines are commercially available, such as silkworm cell lines and mosquito cell lines.
[0087] The target arbovirus grows unhindered in insect cells. Therefore, the target arbovirus carrying the dysfunctional furin cleavage site grows, replicates, matures, and can be released into the environment by the host insect cell to about the same extent or at the same level as the wild-type arbovirus. Therefore, the target arbovirus can produce the same degree or higher levels of progeny virus compared to the arbovirus that does not contain the dysfunctional furin cleavage site in the insect cell.
[0088] The degree of progeny virus production (or proliferation) can be assessed, for example, by plaque assay or hemagglutinin assay, as known in the art and as taught herein. A simple and sensitive method for assessing virus production is to count fluorescently labeled cells in a flow cytometer, as described in Drayman & Oppenheim, "Rapid Titration of Viruses by Flow Cytometry," Curr Prot Cell Biol 26.11.1-26.11.7, 2011. Therefore, serially diluted infected cells are collected (separated if necessary), collected cells, fixed and exposed to one or more antibody reagents, wherein there is at least one Ab for a viral protein and at least one fluorescently labeled Ab, and then at least about 10,000 cells are read, for example, by a flow cytometer, to display the number of fluorescently labeled cells expressing the viral protein. Thus, the arbovirus of interest can produce about the same level or amount or more of progeny virus as compared to the amount of progeny virus produced by cells infected with a reference arbovirus (e.g., for DV, serotype 2, New Guinea strain, ATCC No. VR-1584) in C6 / 36 cells (ATCC Accession No. CRL-1660), or compared to the amount of progeny virus produced by a wild-type virus of the same strain or lineage that does not contain a mutant virus of interest (including enhanced furin activity or exhibiting enhanced furin cleavage of prM).
[0089] The target arbovirus does not properly mature in mammalian cells, the particles are not released (or do not proliferate) by the host mammalian cells, but rather the immature particles are trapped in the host mammalian cells and accumulate therein. Therefore, the target arbovirus produces little or no progeny virus in human or mammalian cells. Compared with the wild-type arbovirus, the target arbovirus produces fewer progeny viruses, for example, 4 logs or less, 5 logs or less, 6 logs or less, 7 logs or less, 8 logs or less, 9 logs or less, or no progeny compared to the number of progeny produced when using HT 1080 cells (ATCC Accession No. CCL-121).
[0090] It is desirable to have mutant viruses that do not proliferate in mammalian cells because it is desirable to minimize or avoid disease or pathology. However, very little to no release of progeny virus is not necessary or essential. Dysfunctional viruses that produce, for example, 4 logs or less, 5 logs or less, 6 logs or less, or less progeny virus when infected in mammalian cells compared to similar cells infected with wild-type virus can be used as immunogens despite the low or low release of progeny virus because the host immune system will eventually clear the virus and cells expressing viral antigens.
[0091] Viruses containing altered and dysfunctional furin sites of interest are infectious but cannot or do not produce infectious progeny virions from infection of mammalian cells. Thus, non-replicating particles are particles that infect host mammalian cells (e.g., human cells), but the host cells do not produce or release progeny virions resulting from the infection. However, the infected mammalian host cells express arboviral epitopes in and on the infected cells.
[0092] The unique properties of the defective target virus provide an effective and safe source of arbovirus immunogenic compositions, and large quantities of virus can be obtained cost-effectively by growing the target virus in insect cells. The functionally impaired target virus can produce approximately the same number of progeny viruses as the reference virus when infected into the same type of insect cells. In an embodiment, the functionally impaired target virus produces more virus from insect cells than the reference virus infected into the insect cell type. In an embodiment, the virus of the functionally impaired target virus is less than the virus produced by the reference virus. A highly immunogenic functionally impaired virus strain mimics the natural infection process of the arbovirus, enabling mammalian hosts to generate and produce long-lasting and extensive arbovirus immunity with no or minimal symptoms. Therefore, the modified target arbovirus is an arbovirus that contains genetic material to express many or all of the epitopes expressed by the wild-type prM, M and E proteins, and possibly the C protein of the wild-type arbovirus.
[0093] The target arbovirus can infect many (if not all) susceptible cells after appropriate titration. The degree of infectivity can be assessed using standard and known assays. For example, Vero cells in a 6-well culture dish are infected with serially diluted arboviruses and the cells are shaken at 37° C. in a shaking platform. The cell culture fluid is collected at 48 h. The amount of virus released into the culture medium can be determined using known methods (e.g., the methods taught herein).
[0094] To prepare partially purified arboviral particles, for example, the culture broth is clarified by centrifugation at 16,000 x g for 15 minutes at 4° C. in a microcentrifuge, and the particles are precipitated from the supernatant by ultracentrifugation at 40,000 rpm for 2 hours at 4° C. in an AH650 rotor in a Sorvall OTD55B centrifuge. The precipitate is resuspended in 50 μl of phosphate buffered saline (PBS) and allowed to dissolve overnight at 4° C.
[0095] To determine the titer of arbovirus, for example, baby hamster kidney (BHK)-21 cells on 8-well chamber slides are infected with 50 μl of serial 10-fold dilutions of cell culture fluid or resuspended pellet material for 2 hours at 37° C. The fluid is then replaced with 1 ml of Dulbecco's minimal essential medium supplemented with 2% fetal bovine serum. The cells are incubated at 37° C. for 24 hours in a CO2 incubator and then subjected to immunofluorescence (IF) analysis using the following substances: arbovirus-specific Ab or mAb (commercially available or prepared as known in the art), HMAF described below or polyclonal antiserum with the necessary specificity, a reagent sandwiched with a virus-specific reagent carrying a detectable reporter molecule, and appropriate controls.
[0096] The virus titer present in the harvested culture fluid (CF) (in infectious units (IU) / ml) is also determined by infection of, for example, rhesus monkey kidney epithelial cells (e.g., LLC-MK2 (ATCC) cells) followed by indirect immunofluorescence analysis (IF) using arbovirus-specific reagents and labeling reagents (e.g., hyperimmune mouse ascites fluid (HMAF) containing mAb).
[0097] Both humoral antibodies and cellular immune responses are associated with protection and recovery from DV infection. The target arboviruses induce a two-armed immune response. These particles are composed of prM, M and / or E proteins, so the target particles are broadly immunogenic and mimic infection with wild-type viruses. However, the target particles infect mammalian host cells, in which additional prM, M and / or E proteins are expressed on or by the host cells. The prM, M and / or E proteins can be released from these cells to provide additional antigenic stimulation to the host, or can be expressed on the surface of infected host cells to provide another mode of antigenic stimulation to the host. The target arbovirus can optionally express non-structural proteins, such as NS1. Previous reports have shown that these NS virus proteins can induce protective immune responses (Heinz & Roehrig, 1990, in, "Immunochemistry of Viruses, Vol II," Amsterdam-NY-Oxford, Elsevier, p. 289-305; Heinz, 1986, Adv Virus Res 31: 103-168; Bray & Lai, 1991, Virol, 185: 505-508; Henchal et al., 1988, J Gen Virol 69: 2101-2107; and Schlesinger et al., 1986, J Virol 60: 1153-1155).
[0098] Suitable models for testing the efficacy of the pharmaceutical composition of interest include animal models that simulate arbovirus infection. For example, a protocol for immunization of mice and subsequent challenge with arbovirus has been documented (Bray et al., 1989, J Virol 63: 2853-2856). Briefly, female BALB / c mice were immunized at 3 weeks of age (day 1) by intraperitoneal (ip) inoculation of virus (such as DV) in each group of 10 mice, and immunized again on day 14. Control animals received phosphate buffered saline (PBS). Blood was collected from all animals on days 0 and 21. In the case of DV, mice were injected intracerebrally with a 50% lethal dose (LD 50 ) was used for challenge. After challenge, the mice were observed for pathological signs for 21 days, and the mice with symptoms (encephalitis, paralysis or death) were recorded every day. Serum was also collected from the survivors for comparison with the serum before challenge.
[0099] The dose of each virus is determined. The serum response of immunized mice to individual arbovirus proteins is analyzed by, for example, ELISA or radioimmunoprecipitation of labeled arbovirus antigens using commercially available labeling kits and antibodies. Plaque reduction assays can be used to measure the titer of arbovirus-specific neutralizing antibodies in mouse serum. For example, about 0.5 ml serum samples to be used in the assay are first heat-inactivated by incubation at 56 ° C for 30 minutes. Four-fold dilutions of serum are prepared with culture medium M199 with 2% heat-inactivated fetal bovine serum (FBS) as diluent, and the final volume is 0.3 ml, starting from a 1:10 dilution. An equal volume of culture medium containing 150-180 plaque forming units (PFU) of virus is added to each 0.3 ml aliquot of diluted serum. The virus is mixed with serum and incubated at 37 ° C for 30 min. In each assay, a serum-free control and a control consisting of each arbovirus type-specific Ab (e.g., at two dilutions) are also included. The virus / serum and control mixtures are plated at 0.2 ml / well on a confluent monolayer of LLC-MK2 cells in, for example, a Costar 6-well plate (Corning Inc., Corning, NY). Duplicate wells are infected for each sample. Virus adsorption is performed at room temperature for 1 hour with manual shaking every 15 minutes. The wells are then covered with 6 ml / well of culture medium containing 1% agarose (SeaKem LE; BioWhittaker, Rockland, ME) in Earle's balanced salt solution (plus 10% FBS, essential vitamins and amino acids (Invitrogen)). The plates are incubated at 37°C for 7 days in 5% CO2. The wells are then covered with a 4% neutral red solution (4 ml neutral red solution added to 96 ml PBS) containing 1% agarose. The plates are incubated at 37°C for 24 hours. The average of the plaque counts is used to calculate a 50% reduction in the number of plaques.
[0100] In embodiments, the viral composition of interest is a multivalent viral composition, i.e., bivalent, trivalent, tetravalent, etc., and is a viral composition that immunizes a host against multiple serotypes of arboviruses, usually one virus, but may include antigens from multiple species (e.g., including multiple mutant viruses of interest). No interference or dominance of one serotype at the expense of one or more other serotypes was observed. This may be because immunogenicity is not dependent on viral production and continued replication of new viruses.
[0101] The arbovirus of interest is incorporated into a pharmaceutical composition suitable for administration as an immunogen, as is known in the art of immunology. Such compositions typically comprise an active ingredient and a pharmaceutically acceptable carrier. As used herein, the phrase "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is known in the art and is a matter of design choice. Unless any conventional media or agents are incompatible with the active compound, their use in the composition is contemplated. Supplementary pharmacologically active compounds, such as adjuvants, may also be incorporated into the composition.
[0102] The pharmaceutical compositions of the invention used as disclosed herein are formulated to be compatible with the intended route of administration.Examples of routes of administration include parenteral, such as intravenous, intradermal, subcutaneous, transdermal (including, for example, topical), transmucosal, and rectal administration.
[0103] Solutions or suspensions for parenteral, intradermal or subcutaneous administration may include the following components: sterile diluents, such as water for injection, saline solution, fixed oils, polyethylene glycol, glycerol, propylene glycol or other synthetic solvents; antibacterial agents, such as benzyl alcohol or methyl paraben; antioxidants, such as ascorbic acid or sodium bisulfite; chelating agents, such as EDTA; buffers, such as acetates, citrates or phosphates; and agents for adjusting tonicity, such as sodium chloride or dextrose, etc. pH can be adjusted with acids or bases (such as HCl or NaOH). Parenteral preparations can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
[0104] Pharmaceutical compositions suitable for injection include sterile aqueous solutions (which are water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor (BASF; Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be liquid to the extent of injectability. The composition must be stable under the conditions of preparation and storage and must be preserved to prevent the contaminating action of microorganisms (such as bacteria and fungi). The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyols (such as glycerol, propylene glycol, liquid polyethylene glycol, etc.) and appropriate mixtures thereof. For example, appropriate fluidity can be maintained by using a coating (such as lecithin), by maintaining the desired particle size in the case of a dispersion, and by using a surfactant. The action of microorganisms can be prevented by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, ascorbic acid, etc. This is achieved. Isotonic agents, such as sugars, polyols (such as mannitol and sorbitol) or sodium chloride, may preferably be included in the composition. Prolonged absorption of injectable compositions can be achieved by adding agents that delay absorption (e.g., aluminum monostearate or gelatin) to the composition.
[0105] Sterile injectable solutions can be prepared by the following steps: the required amount of active compound is incorporated into an appropriate solvent, and one or more components are added as required, followed by filtration sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile carrier containing a basic dispersion medium and the required other ingredients as described above. In the case of sterile powders for the preparation of sterile injectable solutions, the preparation methods include vacuum drying and freeze drying, which produce a powder of the active ingredient plus any other desired ingredients from its previously sterile filtered solution.
[0106] Oral compositions generally include an inert diluent or edible carrier. The composition can be enclosed in a gelatin capsule or compressed into a tablet (coated or treated), for example, to provide an enteric composition, a delayed release formulation, etc. For the purpose of oral therapeutic administration, the active compound can be mixed with an excipient and used in the form of a tablet, a troche, or a capsule. Oral compositions can also be prepared using a liquid carrier to produce a syrup, an elixir, or a liquid preparation, or used as a mouthwash, wherein the compound in the liquid carrier is orally administered, swish, expectorated, or swallowed.
[0107] Pharmaceutically compatible binders and / or adjuvant materials may be included as part of the composition. Tablets, pills, capsules, lozenges, etc. may contain any of the following ingredients or compounds of similar properties: binders, such as microcrystalline cellulose, tragacanth or gelatin; excipients, such as starch or lactose; disintegrants, such as alginic acid, Primogel or corn starch; lubricants, such as magnesium stearate or Sterotes; glidants, such as colloidal silicon dioxide; sweeteners, such as sucrose or saccharin; or flavorings, such as mint, methyl salicylate or orange flavoring. The target particles may be encapsulated in a form that survives passage through the gastric environment. This form is generally referred to as an enteric-coated preparation.
[0108] For administration by inhalation, the compound can be delivered, for example, in the form of a spray, from a pressurized container or dispenser containing a suitable propellant (e.g., a gas such as carbon dioxide or an atomizer or mist). The formulation can be a liquid, a dry powder (e.g., a finely divided powder), or the like.
[0109] Systemic administration can also be carried out by transmembrane or transdermal means. For transmembrane or transdermal administration, a penetrant suitable for the barrier to be penetrated is used in the formulation. Such penetrants are generally known in the art and can include, for example, detergents, bile salts and fusidic acid derivatives for transmembrane administration. Transmembrane administration can be completed by using nasal sprays or enemas. For transdermal administration, the active compound can be formulated into an ointment, salves, foams, gels or creams as generally known in the art. The composition can be delivered using a patch applied to the skin.
[0110] When the intended composition is in the form of a suppository, it may contain conventional suppository bases such as cocoa butter and other glycerides.
[0111] In an embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, for example, in a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid.
[0112] Methods for the preparation of such formulations will be apparent to those skilled in the art. These materials can be obtained from commercial sources such as Johnson & Johnson and Encapsula Nano Sciences (Brentwood, TN).
[0113] Liposomal suspensions (including liposomes targeted with monoclonal antibodies and other such targeting molecules) can also be used as pharmaceutically acceptable carriers. Those can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.
[0114] For ease of administration and uniformity of dosage, it is advantageous to formulate oral or parenteral compositions in unit dosage form. "Unit dosage form" as used herein refers to physically discrete units suitable as unitary dosages for the subjects to be treated; each unit contains a predetermined quantity of active compound calculated to produce the desired therapeutic effect, in association with the required pharmaceutical carrier.
[0115] The pharmaceutical compositions can be included in a container, pack, kit, or dispenser together with instructions for administration.
[0116] Another method of administration includes adding the compound of interest to or with food or beverages, as a dietary supplement or additive, or as a dosage form taken on a preventive basis, similar to vitamins.
[0117] Dosages (e.g., preferred routes of administration and amounts) can be based on empirical data obtained from preclinical and clinical studies by implementing methods known in the art. For repeated administrations over several days or longer, depending on the condition, treatment is continued until the desired suppression of disease symptoms occurs. However, other dosage regimens may be used. The progress of treatment is monitored by conventional techniques and assays. An exemplary dosing regimen is disclosed in WO 94 / 04188. The specifications of the unit dosage forms of the present invention are determined by and can be directly dependent on the unique characteristics of the active compound and the specific therapeutic effect to be achieved and the limitations inherent in the art of formulating such active compounds to treat individuals. Therefore, the number of viral particles administered to adult humans can be extrapolated from the therapeutic amount delivered to model animals (e.g., mice, rats, monkeys, etc.). For example, based on mouse studies, approximately 10 6 Particles (or IU), about 10 7 Particles, about 10 8 Particles, about 10 9 Particles or more may be administered in a single dose or divided doses. As known in the art, the amount or dose may be adjusted as empirical data becomes available.
[0118] The purpose virus can be used to produce an effective immune response in an individual, wherein effectively includes minimizing, reducing or preventing symptoms or symptoms in an individual. Since the host immune response is decisive in obtaining a therapeutic response, it can be graded in any individual like any drug, and the purpose virus may or may not be therapeutic, and may or may not produce a desired response from a viral receptor. The use of dosage, viral presentation pathways and means, adjuvants and other immunological factors can solve the problem of a lack of host immune response or a weaker (tepid) host immune response in an individual.
[0119] This phenomenon is evident at the population level, where not every receptor in the target virus population will generate a therapeutic immune response, and the number of responders in any one population may differ from that in another.
[0120] The utility of a dysfunctional virus of interest does not depend on a greater proportion of responders in a population, a higher level of immune protection in a population, commercial viability, commercial success, etc., but rather that the dysfunctional virus of interest produces a therapeutic immune response that reduces or prevents symptoms or disease even in only one individual.
[0121] The invention will now be illustrated in the following non-limiting examples.
[0122] Example 1
[0123] The DV virion is composed of 6% RNA, 66% protein, 9% carbohydrate and 17% lipid (Russell et al., Chemical and Antigenic Structure of Flaviviruses, in, Schlesinger eds., "The Togaviruses: Biology, Structure, Replication," New York, Academic, 1980, p. 503-529; and Trent & Naeve, Biochemistry and Replication, in Monath, ed., "St. Louis Encephalitis," Washington, DC, American Public Health Association, 1980, p. 159-199). The electron-dense nucleocapsid is composed of C (capsid) protein and genomic RNA. The envelope protein E and membrane (M) protein are embedded in the lipid bilayer through the C-terminal hydrophobic anchor. However, immature particles found in intracellular vesicles contain completely unprocessed pre-M (prM) and are less infectious than released virions (Morens, Clin Infect Dis, 1994, 19: 500-512).
[0124] The genome of DV is a homogeneous, single-stranded, positive-sense RNA molecule of approximately 10-11 kb, containing a single ORF that accounts for approximately 95% of the genome (Chambers et al., Ann Rev Microbiol, 1990, 44: 649-688). The full-length genomic RNA appears to be the only virus-specific messenger RNA (mRNA) molecule in DV-infected cells. During infection, the viral RNA is translated into a polyprotein of approximately 3400 amino acids, which is processed into 10 gene products: three structural proteins, C, prM and E; and seven nonstructural (NS) proteins, 1, 2A, 2B, 3, 4A, 4B and 5 (Bhamarapravati & Yokan, Live attenuated tetravalent vaccine, in Gubler & Kuno, eds., "Dengue and Dengue Hemorrhagic Fever," Wallingford, CAB International, 1997, pp 367-377; and Falgout & Markoff, 1995, The family flaviviridae and its diseases, p. 47-66, in, Porterfield, ed., "Exotic Viral Infections," Chapman and Hall Medical, London, United Kingdom).
[0125] Example 2
[0126] The mutant DV was generated from a full-length infectious cDNA clone of the DV2 New Guinea C strain (ATCC No. VR-1584). The mutant DNA fragment was generated by PCR and introduced into the full-length clone by homologous recombination as described (Zeng et al., J Virol. 1998 Sep; 72(9): 7510-22). The mutation was confirmed by DNA sequencing. RNA of the mutant DV was synthesized by in vitro transcription as described by Polo et al., J Virol. 1997; 71(7): 5366-74.
[0127] Growth kinetics of mutant DVs show differences in virus growth between infected Vero cells (ATCC CCL-81) (human) and infected C6 / 36 cells (CRL-1660) (mosquito). The growth of wild-type DV2 (DENV2) prM (SEQ ID NO: 3) and four mutants in which the Glu in the furin recognition site (E of DENV2) was replaced with Arg (R) (D2-89R, SEQ ID NO: 4), Val (V) (D2-89V, SEQ ID NO: 5), Ser (S) (D2-89S, SEQ ID NO: 6) or Gly (G) (D2-89G, SEQ ID NO: 7) were tested in human Vero cells and mosquito C6 / 36 cells.
[0128] The D2-89R mutant, in which Glu is replaced by R, was propagated in insect cells and showed no replication in human cells.
[0129] Example 3
[0130] The mutants were generated from a full-length infectious cDNA clone from DV1, Western Pacific, strain 74 (Genbank No. U88536) using a second serotype of DV. The mutant DNA fragment was generated by PCR and introduced into the full-length clone by homologous recombination as described (arkoff et al., J Virol. 2002; 76(7):3318-28). The mutations were confirmed by DNA sequencing. RNA of the mutant DV was synthesized by in vitro transcription as described by Polo et al.
[0131] Growth kinetics of DV mutants show differences in virus growth between infected Vero cells (ATCC CCL-81) (human) and infected C6 / 36 cells (CRL-1660) (mosquito).
[0132] Example 4
[0133] The DV1 mutant was prepared as described in Examples 2 and 3 and contained the following sequence:
[0134] CSQTGEHRRRKRSVALAPHVGLGLETRTETWMSSEGAWKHA QRIETWILRH (SEQ ID NO: 17).
[0135] The sequence starts from amino acid 80 of the DV1 prM polypeptide, and in the consensus furin tetrapeptide, D is changed to R. In the above sequence, cleavage occurs between R and S.
[0136] Growth kinetics of mutant DV1 showed differences in virus growth between infected Vero cells (ATCC CCL-81) (human) and infected C6 / 36 cells (CRL-1660) (mosquito).
[0137] Example 5
[0138] Western blot analysis using commercially available DV prM mAb using known methods and comparing band intensity and band size to infer molecular weight showed that the furin cleavage efficiency of mutant DV was increased in both Vero cells (CCL-81) and C6 / 36 cells (CRL-1660).
[0139] Example 6
[0140] The growth of mutant DV in mammalian cells was studied by indirect immunofluorescence staining. mAb 4G2 from ATCC (HB-112) was used in the method of Polo et al.
[0141] For the positive control using the parental DV2 virus, positive fluorescence with increasing brightness and increasing number of positive cells was observed from 1 to 3 days after infection. On the other hand, when the mutant D2-89R was used for infection, the intensity and number of fluorescent cells gradually decreased during this period. No new colonies were formed from 1 to 3 days after infection.
[0142] Therefore, mutant D2-89R induces only a single round of infection in human cells and does not produce infectious progeny virions.
[0143] Example 7
[0144] To verify that mutant D2-89R is growth restricted in human cells, skin fibroblasts (CRL-2522, ATCC) were infected in vitro with DV2 or D2-89R and the presence of viral envelope antigens was assessed by immunofluorescence at different times (hours) post-infection (hpi) as described herein. DV2 proliferated and produced progeny virus in CRL-2522 cells, while mutant D2-89R did not.
[0145] The production of viral particles was observed to increase gradually over time in cells infected with wild-type DV2 virus, indicating active viral replication in the infected cells.
[0146] On the other hand, cells infected with mutant D2-89R did not produce any viral progeny.
[0147] Example 8
[0148] To evaluate the protective efficacy of mammalian cell-specific growth restriction of the mutant DV of interest against DV challenge, groups of 6-week-old AG129 mice (N=6 / group) were subjected to 10 5 A single intraperitoneal (ip) immunization of mutant D2-89R with 100 infectious units (IU) of D2-89R was performed. A control group of mice was injected intraperitoneally (ip) with 50 μl of phosphate buffered saline (PBS).
[0149] The two groups of mice did not show any significantly different mobility or behavior after immunization.
[0150] Ten days after immunization, D2-89R-injected mice and PBS-controlled AG129 mice were injected intraperitoneally (ip) for 10 5 Plaque forming units (PFU) of DV2 (which is 100 times the LD 50 vaccination).
[0151] PBS-injected control mice vaccinated with DV2 developed viremia. In contrast, a single immunization with mutant D2-89R provided complete protection against DV2 challenge without detectable viremia (<100 copies / ml) at any time point (N=10).
[0152] Furthermore, all mice exposed to D2-89R remained healthy throughout the experiment, whereas all mice exposed to PBS alone died after DV2 challenge, see Figure 1 .
[0153] Example 9
[0154] To evaluate the safety of DV mutants, AG129 mice were used because AG129 mice can be lethally infected with as little as 1 PFU of virus from DV2.
[0155] A group of 6 adult AG129 received 10 6 IU of mutant D2-89R, intraperitoneally (ip). For the control group, an equal number of mice in each group were injected intraperitoneally (ip) with 10 1 , 10 2 and 10 3 PFU of DV2. Viral loads after DV2 and D2-89R injection were quantified by RT-PCR.
[0156] The group of mice infected with DV2 developed detectable viremia and all died after infection.
[0157] On the other hand, mice exposed to mutant D2-89R had no detectable viremia, and all mice survived the experimental period (15 days) without any signs of disease and weight changes.
[0158] Example 10
[0159] The electron-dense nucleocapsid of ZV is composed of C (capsid) protein and genomic RNA. The envelope protein E and membrane (M) protein are embedded in the lipid bilayer (Russell et al., Chemical and Antigenic Structure of Flaviviruses, in Schlesinger, ed., The Togaviruses: Biology, Structure, Replication. New York: Academic; 1980: 503-529; and Trent & Naeve, Biochemistry and Replication, in Monath, ed. St. Louis Encephalitis. Washington, DC: American Public Health Association; 1980 p. 159-199).
[0160] The ZV genome is a single-stranded positive-sense RNA molecule of about 10-11 kb, containing a single ORF, which accounts for about 95% of the genome (Chambers et al., Ann Rev Microbiol 1990, 44: 649-688). During infection, the infectious viral RNA is translated and processed into structural and non-structural proteins (Bhamarapravati & Yokan: Live attenuated tetravalent vaccine, in Gubler & Kuno, eds., Dengue and Dengue Hemorrhagic Fever. Wallingford, CAB International, 1997, pp 367-377; and Falgout & Markoff, 1995, The family flaviviridae and its diseases, p. 47-66. in: JS Porterfield (ed.), Exotic Viral Infections. Chapman and Hall Medical, London, United Kingdom).
[0161] Embodiment 11
[0162] A full-length infectious cDNA clone of ZV MR766 from ATCC was subjected to point mutations to produce growth restriction in mammalian cells. The mutations were confirmed by DNA sequencing. Mutant ZV genomic RNA was synthesized by in vitro transcription and expressed as 50 μg / mL by PCR according to the manufacturer's instructions. C6 / 36 mosquito cells were transfected with mutant viral RNA (Mirus Bio, Madison, WI). Mutant ZV was harvested 7 days after transfection. Virus growth kinetics were determined in mammalian (Vero) cells and C6 / 36 cells.
[0163] Point mutations were induced in the ZV genome to alter the sequence near the furin cleavage site as shown below:
[0164] wild type:
[0165] HHKKGEARRSRRAVTLPSHSTRKLQTRSQTWLESREYTKHIK VENWIFRN(SEQ ID NO:11)
[0166] Mutants:
[0167] HHKKGEARR R RRAVTLPSHSTRKLQTRSQTWLESREYTKHIKVENWIFRN (SEQ ID NO: 12).
[0168] A single change from serine to arginine resulted in decreased proliferation in Vero cells, whereas proliferation in mosquito cells remained relatively unchanged compared to controls.
[0169] Example 12
[0170] The method of Example 11 was followed. The same Ser to Arg substitution was used and Glu (E) (between G and A) was replaced with His (H) to generate a mutant with two point mutations.
[0171] Proliferation in human cells was reduced to levels below that observed with the mutant of Example 11, but replication in insect cells was not affected.
[0172] Example 13
[0173] The method of Example 11 was followed. The first 12 amino acids of the sequence given in Example 11 were replaced by TTTGEHRRRKRS (SEQ ID NO: 13).
[0174] Proliferation in human cells was reduced to levels below that observed with the mutant of Example 11, but replication in insect cells was not affected.
[0175] Embodiment 14
[0176] The method of Example 11 was followed. The first 22 amino acids of the sequence given in Example 11 were replaced by TTTGEHRRRKRSVALVPHVGMG (SEQ ID NO: 14).
[0177] Proliferation in human cells was reduced to levels below that observed with the mutant of Example 11, but replication in insect cells was not affected.
[0178] Embodiment 15
[0179] The method of Example 11 was followed. The first 37 amino acids of the sequence given in Example 11 were replaced by TTTGEHRRRKRSVALVPHVGMGLETRTETWMSSEGAW (SEQ ID NO: 15) to form the ZV M2 mutant.
[0180] Proliferation in human cells was reduced to levels below that observed with the mutant of Example 11, but replication in insect cells was not affected.
[0181] Example 16
[0182] To evaluate the protective efficacy of mammalian cell-specific growth restriction of the target mutant SV against SV challenge, groups of 6-week-old AG129 mice (N=6 / group) were subjected to 10 5 Single intraperitoneal (ip) immunization of 100 infectious units (IU) of mutant M2 of Example 15. Control mice were injected intraperitoneally (ip) with 50 μl PBS.
[0183] The two groups of mice did not show any significantly different movements and behaviors after immunization.
[0184] 14 days after immunization, M2-injected mice and PBS-controlled AG 129 mice were injected intraperitoneally (ip) with 10 3 Plaque forming units (PFU) of wild-type SV (which is 100 times the LD 50 vaccination).
[0185] Control mice injected with PBS developed viremia after SV vaccination. In contrast, a single immunization with mutant M2 provided complete protection against SV challenge at any time point (N=10) without detectable viremia (<100 copies / ml).
[0186] Furthermore, all mice exposed to M2 remained healthy throughout the experiment, whereas all mice exposed only to PBS died after SV challenge, see Figure 2 .
[0187] Embodiment 17
[0188] To evaluate the safety of mammalian cell-specific growth restriction of the mutant SV of interest, groups of 6-week-old AG129 mice (N=6 / group) were subjected to 10 5 A single intraperitoneal (ip) immunization with infectious units (IU) of mutant M2 or wild-type ZV was performed.
[0189] Mice exposed to M2 were healthy throughout the experiment, whereas all mice exposed to PBS alone died after SV challenge, see Figure 3 .
[0190] Embodiment 18
[0191] The materials and methods of Examples 2-9 were performed using a typical strain of yellow fever virus.
[0192] Position the prM furin recognition site, and carry out amino acid replacement according to the mode provided above and known in the art.Target mutants are identified as those mutants that no longer proliferate or proliferate with lower levels in human cells, as provided above.Amino acid changes, such as displacement, insertion, disappearance, chemical modification, etc., are also carried out in the upstream and / or downstream of the furin cleavage site.
[0193] Yellow fever virus mutants that replicate in insect cells but less successfully in human cells were identified.
[0194] Embodiment 19
[0195] The materials and methods of Examples 2-9 were performed using a typical strain of California encephalitis virus.
[0196] Position the prM furin recognition site, and carry out amino acid replacement according to the mode provided above and known in the art.Target mutants are identified as those mutants that no longer proliferate or proliferate with lower levels in human cells, as provided above.Amino acid changes, such as displacement, insertion, disappearance, chemical modification, etc., are also carried out in the upstream and / or downstream of the furin cleavage site.
[0197] A California encephalitis virus mutant was identified that replicates in insect cells but less successfully in human cells.
[0198] Embodiment 20
[0199] The materials and methods of Examples 2-9 were performed using a representative strain of Rift Valley fever virus.
[0200] Position the prM furin recognition site, and carry out amino acid replacement according to the mode provided above and known in the art.Target mutants are identified as those mutants that no longer proliferate or proliferate with lower levels in human cells, as provided above.Amino acid changes, such as displacement, insertion, disappearance, chemical modification, etc., are also carried out in the upstream and / or downstream of the furin cleavage site.
[0201] Rift Valley fever virus mutants that replicate in insect cells but less successfully in human cells were identified.
[0202] Embodiment 21
[0203] The materials and methods of Examples 2-9 were performed using a representative strain of tick-borne encephalitis virus.
[0204] Position the prM furin recognition site, and carry out amino acid replacement according to the mode provided above and known in the art.Target mutants are identified as those mutants that no longer proliferate or proliferate with lower levels in human cells, as provided above.Amino acid changes, such as displacement, insertion, disappearance, chemical modification, etc., are also carried out in the upstream and / or downstream of the furin cleavage site.
[0205] Tick-borne encephalitis virus mutants that replicate in insect cells but less successfully in human cells were identified.
[0206] Embodiment 22
[0207] The materials and methods of Examples 2-9 were performed using a representative strain of West Nile virus.
[0208] Position the prM furin recognition site, and carry out amino acid replacement according to the mode provided above and known in the art.The target mutant is identified as those mutants that no longer proliferate or proliferate with lower levels in mammalian cells, as provided above.Amino acid whose change, such as displacement, insertion, disappearance, chemical modification etc., is also carried out in the upstream and / or downstream of the furin cleavage site.
[0209] West Nile virus mutants that replicate in insect cells but less successfully in mammalian cells were identified.
[0210] Embodiment 23
[0211] The materials and methods of Examples 2-9 were performed using a representative strain of equine encephalopathy virus.
[0212] Position the prM furin recognition site, and carry out amino acid replacement according to the mode provided above and known in the art.The target mutant is identified as those mutants that no longer proliferate or proliferate with lower levels in mammalian cells, as provided above.Amino acid whose change, such as displacement, insertion, disappearance, chemical modification etc., is also carried out in the upstream and / or downstream of the furin cleavage site.
[0213] Mutants of equine encephalopathy virus that replicate in insect cells but less successfully in mammalian cells were identified.
[0214] Embodiment 24
[0215] The materials and methods of Examples 2-9 were performed using a representative strain of Colorado tick fever virus.
[0216] Position the prM furin recognition site, and carry out amino acid replacement according to the mode provided above and known in the art.Target mutants are identified as those mutants that no longer proliferate or proliferate with lower levels in human cells, as provided above.Amino acid changes, such as displacement, insertion, disappearance, chemical modification, etc., are also carried out in the upstream and / or downstream of the furin cleavage site.
[0217] Colorado tick fever virus mutants were identified that replicate in insect cells but less successfully in human cells.
[0218] Embodiment 25
[0219] The materials and methods of Examples 2-9 were performed using a representative strain of Chikungunya virus.
[0220] Position the prM furin recognition site, and carry out amino acid replacement according to the mode provided above and known in the art.Target mutants are identified as those mutants that no longer proliferate or proliferate with lower levels in human cells, as provided above.Amino acid changes, such as displacement, insertion, disappearance, chemical modification, etc., are also carried out in the upstream and / or downstream of the furin cleavage site.
[0221] Chikungunya virus mutants that replicate in insect cells but less successfully in human cells were identified.
[0222] Embodiment 26
[0223] The materials and methods of Examples 2-9 were carried out using a typical strain of African swine fever virus.
[0224] Position the prM furin recognition site, and carry out amino acid replacement according to the mode provided above and known in the art.Target mutants are identified as those mutants that no longer proliferate or proliferate with lower levels in human cells, as provided above.Amino acid changes, such as displacement, insertion, disappearance, chemical modification, etc., are also carried out in the upstream and / or downstream of the furin cleavage site.
[0225] African swine fever virus mutants that replicate in insect cells but less successfully in human cells were identified.
[0226] Embodiment 27
[0227] Adult rhesus monkeys were divided into experimental and control groups, with 4-6 animals in each group. The experimental group received different doses (10 5 -10 10 IU) of the mutant D2-89R of Example 2. The animals in the control group received an equal volume of PBS.
[0228] During this period, the animals were housed for 4 weeks and tested for circulating anti-dengue antibodies, viral load and cellular immunofluorescence to detect the presence, extent and amount of the virus and the host response to it, and monitored for any symptoms of dengue infection, such as fever and weight loss.
[0229] Animals were then challenged with wild-type DV2 and monitored for symptoms (such as fever and weight loss) and serological parameters (such as viral load and dengue antibodies).
[0230] Control animals showed symptoms of dengue infection, while monkeys that received the mutant of interest were asymptomatic.
[0231] Embodiment 28
[0232] Adult rhesus monkeys were divided into experimental and control groups, with 4-6 animals in each group. The experimental group received different doses (10 5 -10 10 IU) of the DV1 mutant of Example 4. Control group animals received an equal volume of PBS.
[0233] During this period, the animals were housed for 4 weeks and tested for circulating anti-dengue antibodies, viral load and cellular immunofluorescence to detect the presence, extent and amount of the virus and the host response to it, and monitored for any symptoms of dengue infection, such as fever and weight loss.
[0234] Animals were then challenged with wild-type DV1 and monitored for symptoms (such as fever and weight loss) and serological parameters (such as viral load and dengue antibodies).
[0235] Control animals showed symptoms of dengue infection, while monkeys that received the mutant of interest were asymptomatic.
[0236] Embodiment 29
[0237] Adult rhesus monkeys were divided into two experimental groups and two control groups, with 4-6 animals in each group. The experimental groups received different doses (10 5 -10 10 IU) of the mutant Zika virus of Example 14. Animals in the control group received an equal volume of PBS.
[0238] During this period, the animals were housed for 4 weeks and tested for circulating anti-Zika antibodies, viral load, and cellular immunofluorescence to detect the presence, extent, and amount of the virus and the host response to it, and monitored for any symptoms of Zika infection, such as fever, viremia, rash, and weight loss.
[0239] The animals were then challenged with wild-type ZV. One experimental and control pair was challenged with wild-type ZV African strain, and the other experimental and control pair was challenged with wild-type ZV Asian strain. The animals were monitored for symptoms (such as fever, rash, and weight loss) and serological parameters (such as viral load and Zika antibodies).
[0240] Control animals showed symptoms of Zika infection, while monkeys that received the mutant of interest were asymptomatic.
[0241] Embodiment 30
[0242] Adult rhesus monkeys were divided into two experimental groups and two control groups, with 4-6 animals in each group. The experimental groups received different doses (10 5 -10 10 IU) of the mutant Zika virus of Example 15. Animals in the control group received an equal volume of PBS.
[0243] During this period, the animals were housed for 4 weeks and tested for circulating anti-Zika antibodies, viral load, and cellular immunofluorescence to detect the presence, extent, and amount of the virus and the host response to it, and monitored for any symptoms of Zika infection, such as fever, viremia, rash, and weight loss.
[0244] The animals were then challenged with wild-type ZV. One experimental and control pair was challenged with wild-type ZV African strain, and the other experimental and control pair was challenged with wild-type ZV Asian strain. The animals were monitored for symptoms (such as fever, rash, and weight loss) and serological parameters (such as viral load and Zika antibodies).
[0245] Control animals showed symptoms of Zika infection, while monkeys that received the mutant of interest were asymptomatic.
[0246] All references cited herein are hereby incorporated by reference in their entirety.
[0247] It should be understood that various changes and modifications to the currently preferred embodiments described herein will be apparent to those skilled in the art. Such changes and modifications may be made without departing from the spirit and scope of the invention and without impairing its expected advantages. Therefore, these changes and modifications are intended to be included in the appended claims.
Claims
1. An arbovirus particle comprising a mutant arbovirus that replicates in insect cells but not in mammalian host cells, the arbovirus comprising a molecularly altered furin tetrapeptide cleavage site in a precursor polyprotein, and optionally, an alteration in a first stretch of amino acids upstream of the site and / or an alteration in a second stretch of amino acids downstream of the site.
2. The particle of claim 1, wherein the site comprises the consensus sequence Arg-X-Lys / Arg-Arg (SEQ ID NO: 16).
3. The particle of claim 2, wherein X comprises Arg.
4. The particle of claim 1, wherein the first stretch comprises 8 amino acids adjacent to the site.
5. The particle of claim 1, comprising an alteration in the first segment.
6. The particle of claim 1, comprising an alteration in the second segment.
7. The particle of claim 1, wherein the multimeric protein comprises prM.
8. The particle of claim 1, wherein the multimeric protein comprises prE2.
9. The particle of claim 1, comprising dengue virus (DV).
10. The particle of claim 1, comprising Zika virus (ZV).
11. A composition comprising the particles of claim 1 and a pharmaceutically acceptable carrier, diluent or excipient.
12. An insect cell comprising the particle of claim 1.
13. The cell of claim 12, wherein the insect comprises an arthropod.
14. The cell of claim 12, wherein the insect comprises a tick or a mosquito.
15. A mammalian cell comprising the particle of claim 1.
16. The cell of claim 15, wherein the cell expresses a DV antigen.
17. The cell of claim 15, wherein the cell expresses a DV antigen on the surface of the cell.
18. The cell of claim 15, wherein the cell expresses a ZV antigen.
19. The cell of claim 15, wherein the cell expresses a ZV antigen on the surface of the cell.
20. The cell of claim 15, which comprises a human cell.
Citation Information
Patent Citations
Poultry litter conditioner and attachment assembly
US20180050341A1
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4522811A
Method for treating an LFA-1-mediated disorder
WO1994004188A1
